Welcome to our dedicated page for Bionano Genomics news (Ticker: BNGO), a resource for investors and traders seeking the latest updates and insights on Bionano Genomics stock.
Bionano Genomics, Inc. (NASDAQ: BNGO) regularly issues news and updates about its genome analysis technologies, financial results and scientific collaborations. The company describes itself as a provider of optical genome mapping (OGM) solutions, diagnostic services and software that support research and clinical research applications in areas such as inherited disease, reproductive disorders, hematologic malignancies, solid tumors and rare diseases.
On this page, readers can follow Bionano’s announcements about quarterly and annual financial results, capital markets transactions, and strategic shifts in its business model. Recent press releases have discussed the company’s focus on routine users of its OGM solutions, trends in consumables and software utilization, and public offerings of common stock and warrants disclosed through SEC filings and corresponding news releases.
Bionano’s news flow also highlights scientific and clinical research progress involving OGM. The company frequently reports on studies presented at major conferences such as the American Society of Human Genetics (ASHG) and the Association for Molecular Pathology (AMP), where researchers have described OGM’s use in detecting structural variants across a range of genetic conditions. In addition, Bionano has drawn attention to peer-reviewed publications, including work from The University of Texas MD Anderson Cancer Center comparing OGM with targeted RNA-sequencing in acute leukemia.
Updates from Bionano Laboratories, the company’s CLIA-certified laboratory business, cover developments in OGM-based laboratory developed tests and reimbursement, including Category I CPT codes 81195 and 81354 for OGM applications in hematologic malignancies and constitutional genetic disease. Investors and researchers can use this news page to review BNGO’s historical and ongoing disclosures about its technology platforms, research collaborations, reimbursement milestones and financial performance.
Bionano Genomics (Nasdaq: BNGO) will participate in the Association for Molecular Pathology (AMP) Annual Meeting and Expo 2022, showcasing optical genome mapping's (OGM) applications, including genetic disease and hematological malignancies. Key presentations include workshops on enhancing detection of pathogenic structural variants, and methodologies for homologous recombination deficiency assessment. The event will highlight OGM's integration with next-generation sequencing. The conference runs from November 1-5, 2022, in Phoenix, Arizona, underscoring OGM's growing recognition in molecular pathology.
Bionano Genomics (BNGO) will host a conference call and live webcast on November 3, 2022, at 4:30 p.m. ET to discuss its Q3 2022 financial results and corporate advancements. Investors can participate via a toll-free number or through a dedicated webcast link. The call will be accessible for replay on Bionano's investor relations website for 30 days following the event. Bionano Genomics focuses on genome analysis solutions, aiming to enhance diagnostics through its various platforms, including Lineagen and BioDiscovery.
Bionano Genomics, Inc. (BNGO) and Hamilton announced the commercial availability of the Long String VANTAGE, an automated system for high throughput isolation of ultra-high molecular weight (UHMW) DNA. This system improves the efficiency of optical genome mapping (OGM) using human blood samples, allowing labs to process up to 24 samples in an eight-hour workday. Shipping is expected to begin in Q1 2023 as part of ongoing collaboration for clinical applications. The development aims to enhance genomic analysis accuracy, reducing hands-on time and improving result consistency.
Bionano Genomics hosted its first "Meet the User" event on October 24, 2022, at its new CLIA-certified laboratories in San Diego. The event gathered over 50 participants from multiple countries, focusing on optical genome mapping (OGM). Attendees experienced hands-on demonstrations of the Saphyr system and NxClinical software, along with educational sessions on data analysis for rare diseases. Bionano aims to enhance OGM adoption and provided insights into their product roadmap, showcasing the growing interest in genomic solutions.
Bionano Genomics (BNGO) announced its participation in the ASHG Annual Meeting 2022, showcasing its optical genome mapping (OGM) technology. Key presentations include a multi-site clinical study of OGM's application in postnatal genetic disorders and significant advancements in molecular cytogenetics. The conference will feature a record 24 scientific presentations on OGM's utility in genetic disease research. Notably, Bionano will present new data from its partnership with Hamilton on the Long String VANTAGE system, enhancing ultra-high molecular weight DNA extraction processes.
Bionano Genomics (BNGO) announced a peer-reviewed study validating optical genome mapping (OGM) for noninvasive prenatal testing (NIPT) results. The research, conducted at Hangzhou Maternity and Child Care Hospital, found OGM effectively identifies complex chromosomal rearrangements (CCR) tied to recurrent pregnancy loss, with 70% of CCR carriers being phenotypically normal. The study demonstrated OGM's capability to reveal significant structural aberrations overlooked by traditional methods, improving prenatal diagnosis and genetic counseling, highlighting its potential for high-risk pregnancies.
Bionano Genomics (BNGO) announced its participation in the Spanish Society of Hematology (SEHH) 2022 Conference, taking place from October 6-8 in Barcelona. The company featured six scientific presentations showcasing the applications of its optical genome mapping (OGM) technology in hematologic malignancies like leukemias and lymphomas. These independent studies emphasize OGM's utility in cancer genomics and cytogenetic diagnosis, potentially positioning it as a vital tool for future cancer research.
Bionano Genomics (BNGO) announced a study revealing the efficacy of optical genome mapping (OGM) in investigating hepatocellular carcinoma (HCC). Published in Cancer Research, the research demonstrated OGM's capability to detect replication stress-induced structural variations (SVs) more effectively than whole genome sequencing (WGS). The study found that OGM identified 1.4 times more SVs than WGS, illustrating its potential in understanding oncogenesis mechanisms. CEO Erik Holmlin highlighted OGM's sensitivity for large SV detection, emphasizing its complementary role alongside WGS.
Bionano Laboratories and OptraHEALTH have announced a collaboration to integrate the HealthFAX AI platform to enhance genetic counseling services. This initiative aims to improve patient care by automating educational workflows and providing tailored information on genetic testing. The partnership is expected to increase efficiency and scale operations, allowing Bionano Laboratories to better serve patients seeking genetic diagnostics. Both companies emphasize the importance of reducing anxiety for families awaiting genetic test results through improved access to information and support.
Bionano Genomics (Nasdaq: BNGO) announced the launch of Bionano Laboratories, merging optical genome mapping (OGM) data services with Lineagen's clinical testing services. The newly CLIA-certified lab aims to develop laboratory developed tests (LDTs), starting with a test for facioscapulohumeral muscular dystrophy (FSHD), a key condition in muscular disorder evaluations. This milestone is expected to enhance diagnostic capabilities and facilitate insurance reimbursements for OGM-based assays, aligning with the company's growth strategy.
FAQ
What is the current stock price of Bionano Genomics (BNGO)?
What is the market cap of Bionano Genomics (BNGO)?
